Ulcerative colitis
Immunology· 8 reviewed drugs· 19033 cited findings behind them
What the regulatory reviews cover
Regulatory review documents in this library for ulcerative colitis include Tremfya, Omvoh, Velsipity, Stelara, Zeposia, Xeljanz, Simponi, and Entyvio. These drugs have been reviewed for the treatment of adult patients with moderately to severely active ulcerative colitis, with some indications also covering pediatric patients or specific patient responses to prior therapies.
Reported results vary across the different drug reviews. For instance, Omvoh showed a Clinical Remission at Week 12 of 23.5 compared to 13.9 for Placebo. Zeposia demonstrated a Proportion of patients in clinical remission of 37 % versus 19 % for placebo. Stelara reported a Clinical Response at Week 6 (Induction Study 3002) of 55.5 %. Entyvio showed Clinical remission at Week 52 (treatment difference vs placebo) of 32. It is important to note that these figures are derived from different trials and are not directly comparable head-to-head.
The drugs — one cited result each
| Tremfya Johnson & Johnson | 4746 cited findings on the drug page → |
| Omvoh Eli Lilly and Company | Clinical Remission at Week 12: 23.5 Eli Lilly and Company — Omvoh FDA Review (BLA761279, ORIG 1,, p.130 |
| Velsipity Pfizer Inc. | 2642 cited findings on the drug page → |
| Stelara Johnson & Johnson | Clinical Response at Week 6 (Induction Study 3002): 55.5 % Johnson & Johnson — Stelara FDA Review (BLA761044, ORIG 1, 2, p.114 |
| Zeposia Bristol-Myers Squibb Company | Proportion of patients in clinical remission: 37 % BRISTOL — Zeposia FDA Review (NDA/BLA 209899, 2023), p.57 |
| Xeljanz Pfizer Inc. | 2401 cited findings on the drug page → |
| Simponi CENTOCOR ORTHO BIOTECH INC | 950 cited findings on the drug page → |
| Entyvio Takeda Pharmaceutical Company Limited | Clinical remission at Week 52 (treatment difference vs placebo): 32 Takeda Pharmaceutical Company Limited — Entyvio FDA Review, p.48 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Immunology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.